Buying pressure lifts AbbVie stock higher in today's trading

Traders Union
All News
Financial News
Abbvie rises 2.42% today on strong news

Highlights

AbbVie launched an 86% lower-cost Humira on TrumpRx after a White House pricing deal, reshaping US drug access and pricing policy.
As part of the agreement, AbbVie pledged $100 billion to US R&D and manufacturing over ten years and received expanded Skyrizi indications.
AbbVie trades below major moving averages, with indicators pointing to weak trend strength and a next-week trading range of $201.51 to $217.93.

Humira price cut and FDA updates reshape US drug strategy

AbbVie has launched an 86% discounted version of Humira on the TrumpRx platform following a pricing agreement with the White House, marking a significant shift in US drug pricing strategy and expanding patient access. The company also committed $100 billion over the next decade to US research, development, and manufacturing investments as part of the same arrangement, which included certain pricing concessions and tariff exemptions. Additionally, AbbVie received a US FDA update to Skyrizi's prescribing information to cover new psoriasis indications, reinforcing its immunology portfolio along with Rinvoq, and declared a quarterly dividend of $1.73 per share following reported quarterly revenue of $16.62 billion.

Anton Kharitonov, expert at Traders Union, sees sustained technical and sentiment pressure on AbbVie. He notes that the price is below all major moving averages, with no key support above $211.36. The recent strategic news, despite its headline appeal, has not led to buyer conviction. Kharitonov remains critical of weak trend signals and the dominant selling, even as news flow attempts to shift sentiment. "Technical fatigue is clear — a true reversal looks unlikely without tangible buying and firm breakouts above $219.42."

Viktoras Karapetjanc, expert at Traders Union, highlights AbbVie's latest strategic moves as a major long-term catalyst. He believes the $100 billion investment and new pricing deal showcase strong commitment to R&D and expanding US access. Positive regulatory updates and dividend stability reinforce institutional confidence. Karapetjanc sees opportunity for further growth once technical resistance is cleared. "These factors point to an underlying bullish structure — further upside is just a matter of timing."

Jainam Mehta, market strategist, observes soft momentum but notes intraday volatility near range highs. He sees the possibility of sideways action unless $219.42 is breached. The current dynamic may set up tactical trades if volatility persists and sentiment shifts. "A break above dynamic resistance could trigger a quick long setup, but below $201.51, bears retain control."

Oversold conditions persist amid weak momentum and resistance overhead

Momentum signals for ABBV remain soft, as the MACD on daily shows a strong sell and the ADX is below 20, indicating weak trend strength. The RSI, Stochastic RSI, and CCI are neutral to slightly oversold, and the Bull/Bear Power is negative, pointing toward dominance by sellers in an oversold condition. Despite subdued momentum, the stock is trading near the high of its daily range with an intraday volatility of 3.21%. The Ichimoku Kijun sits overhead at $219.42 as dynamic resistance, with no moving average support present above the current price.

Earlier, analysts noted that AbbVie shares were under persistent selling pressure, with technical signals indicating a predominantly bearish outlook. The latest developments—particularly the major Humira price cut, fresh FDA updates, and a continued lack of technical buy signals—reinforce this cautious stance, with traders advised to watch for a decisive break of the $219.42 resistance or a fall below $201.51 to confirm the next directional move.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.